Sinphar Pharmaceutical Co (TPE:1734) EPS (Basic): NT$1.92 (TTM As of Dec. 2025)

What is Sinphar Pharmaceutical Co EPS (Basic)?

Sinphar Pharmaceutical Co TPE:1734 +0.15% 82 EPS (Basic) is NT$1.92 as of Dec. 2025. GuruFocus rates TPE:1734 with a GF Score™ of 82/100 and a GF Value™ of NT$33.13 (Fairly Valued). The stock has 1 warning sign investors should review.

Sinphar Pharmaceutical Co's basic earnings per share (Basic EPS) for the three months ended in Dec. 2025 was NT$0.53. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$1.92.

Sinphar Pharmaceutical Co's EPS (Diluted) for the three months ended in Dec. 2025 was NT$0.53. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$1.92.

Sinphar Pharmaceutical Co's EPS without NRI for the three months ended in Dec. 2025 was NT$0.53. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was 1.92.

During the past 12 months, Sinphar Pharmaceutical Co's average EPS without NRIGrowth Rate was 19.90% per year. During the past 3 years, the average EPS without NRI Growth Rate was 17.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Sinphar Pharmaceutical Co's highest 3-Year average EPS without NRI Growth Rate was 149.70% per year. The lowest was -81.70% per year. And the median was 5.70% per year.

Sinphar Pharmaceutical Co (TPE:1734) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Sinphar Pharmaceutical Co EPS (Basic) Related Terms

Sinphar Pharmaceutical Co EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Sinphar Pharmaceutical Co's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinphar Pharmaceutical Co EPS (Basic) Chart

Sinphar Pharmaceutical Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EPS (Basic)

Get a 7-Day Free Trial

-0.20

1.18

1.97

1.60

1.92

Sinphar Pharmaceutical Co Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
EPS (Basic)	Get a 7-Day Free Trial															0.43	0.59	0.36	0.44	0.53

82GF Score

Sinphar Pharmaceutical Co Ltd TPE:1734

EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Sinphar Pharmaceutical Co EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Sinphar Pharmaceutical Co's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(365.751	-	0)	/	190.197
	=	1.92

Sinphar Pharmaceutical Co's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(101.951	-	0)	/	190.197
	=	0.54

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1.92

Frequently Asked Questions Learn more about EPS (Basic) →

What does a EPS (Basic) of NT$1.92 mean?

Sinphar Pharmaceutical Co (TPE:1734) has a EPS (Basic) of NT$1.92 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Sinphar Pharmaceutical Co and its competitors.

Is Sinphar Pharmaceutical Co's EPS (Basic) too high?

Sinphar Pharmaceutical Co's current EPS (Basic) is NT$1.92. Overall, Sinphar Pharmaceutical Co has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does Sinphar Pharmaceutical Co's EPS (Basic) compare to VRTX and REGN?

Sinphar Pharmaceutical Co's EPS (Basic) of NT$1.92 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EPS (Basic) for a Biotechnology company?

A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EPS (Basic) mean?

A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Sinphar Pharmaceutical Co and its competitors. Sinphar Pharmaceutical Co's current EPS (Basic) is NT$1.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Sinphar Pharmaceutical Co stock overvalued right now?

Based on GuruFocus' analysis, Sinphar Pharmaceutical Co (TPE:1734) is currently considered Fairly Valued. The stock's GF Value™ is NT$33.13, compared to a current price of NT$32.35 — trading 2.4% below its estimated fair value. The current EPS (Basic) is NT$1.92. Sinphar Pharmaceutical Co's overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EPS (Basic) calculated?

EPS (Basic) is calculated from a company's financial statements. For Sinphar Pharmaceutical Co (TPE:1734), the current EPS (Basic) is NT$1.92 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sinphar Pharmaceutical Co (TPE:1734) Overvalued in 2026?

Based on GuruFocus' analysis, Sinphar Pharmaceutical Co stock appears to be undervalued. The current stock price of NT$32.35 is trading 2.4% below its estimated GF Value™ of NT$33.13. GuruFocus considers Sinphar Pharmaceutical Co to be Fairly Valued.

Key valuation signals for TPE:1734:

EPS (Basic): NT$1.92
GF Value™: NT$33.13 vs. price of NT$32.35 (2.4% below fair value)
GF Score™: 82/100 with 1 warning sign

No single metric tells the full story. See the TPE:1734 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sinphar Pharmaceutical Co Business Description

Industry Healthcare Biotechnology

Comparable Companies ROCO:7754 ROCO:4726 ROCO:4167 ROCO:6610 ROCO:6748 ROCO:4157 TPE:1760 ROCO:7729 TPE:6794 ROCO:7832 VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address No.84, Zhongshan Road, Dongshan Township, Zhongshan Village, Yilan, TWN, 269

Website https://www.sinphar.com

Sinphar Pharmaceutical Co Ltd operates in the pharmaceutical segment. The company mainly engages in the production, processing, and trading of various Chinese medicines, medicinal cosmetics, and nutrients. The company's reportable segments are; Pharmaceuticals which derives key revenue, Healthy food, and others. Geographically, the company generates a majority of its revenue from Taiwan and the rest from China, Vietnam, Indonesia, America, and other regions.

82GF Score

Get the complete analysis for TPE:1734

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$32.35

Price

NT$33.13

GF Value

View TPE:1734 Analysis

See EPS (Basic) data for all stocks →